SMAGP

Across TCGA pan-cancer cohorts, SMAGP Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SMAGP data layer compared with 29 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SMAGP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMAGP expression acts as an unfavorable survival marker.

LIHC and SKCM are the cancer types where SMAGP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.144	0.707	<.001	18	view →
SKCM	DFS	Median	All	0.046	0.757	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SMAGP–LIHC (OS)

Open the LIHC breakdown →